SAN DIEGO, Dec. 5, 2011 (GLOBE NEWSWIRE) -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) (“TearLab” or the “Company”) announced today that it is in receipt of a communication from the U.S. Food and Drug Administration (“FDA”) indicating that, based on a supervisory review of the Company’s appeal, the Agency has granted its petition for a waiver under CLlA for the TearLab® Osmolarity System. Upon the Company’s submission of labeling acceptable to the Agency, the CLIA waiver will be issued.
